Engineering multiple U7snRNA constructs to induce single and multiexon-skipping for Duchenne muscular dystrophy.

Engineering multiple U7snRNA constructs to induce single and multiexon-skipping for Duchenne muscular dystrophy.

Εμφάνιση άλλων εκδόσεων (1)

Duchenne muscular dystrophy (DMD) is a fatal muscle wasting disorder caused by mutations in the dystrophin gene. Antisense-mediated exon skipping is one of the most promising approaches for the treatment of DMD but still faces personalized medicine challenges as different mutations found in DMD pati...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Goyenvalle, A, Wright, J, Babbs, A, Wilkins, V, Garcia, L, Davies, K
Μορφή:	Journal article
Γλώσσα:	English
Έκδοση:	2012

Παρόμοια τεκμήρια

Engineering multiple U7snRNA constructs to induce single and multiexon-skipping for Duchenne muscular dystrophy
ανά: Goyenvalle, A, κ.ά.
Έκδοση: (2012)

AAV-U7snRNA mediated multi exon-skipping for Duchenne muscular dystrophy
ανά: Goyenvalle, A, κ.ά.
Έκδοση: (2011)

AAV-U7snRNA mediated multi exon-skipping for Duchenne muscular dystrophy
ανά: Goyenvalle, A, κ.ά.
Έκδοση: (2010)

Engineering exon-skipping vectors expressing U7 snRNA constructs for Duchenne muscular dystrophy gene therapy.
ανά: Goyenvalle, A, κ.ά.
Έκδοση: (2011)

Assessment of the feasibility of exon 45–55 multiexon skipping for duchenne muscular dystrophy
ανά: van Ommen Gert-Jan B, κ.ά.
Έκδοση: (2008-12-01)

Upgrading U7snRNA To Complete Efficient Rescue of Dystrophin by Exon-Skipping in DMD Patients
ανά: Goyenvalle, A, κ.ά.
Έκδοση: (2009)

Rescue of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skipping
ανά: Goyenvalle, A, κ.ά.
Έκδοση: (2012)

Rescue of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skipping.
ανά: Goyenvalle, A, κ.ά.
Έκδοση: (2012)

Enhanced exon-skipping induced by U7 snRNA carrying a splicing silencer sequence: Promising tool for DMD therapy.
ανά: Goyenvalle, A, κ.ά.
Έκδοση: (2009)

The Cellular Processing Capacity Limits the Amounts of Chimeric U7 snRNA Available for Antisense Delivery.
ανά: Eckenfelder, A, κ.ά.
Έκδοση: (2012)

The Cellular Processing Capacity Limits the Amounts of Chimeric U7 snRNA Available for Antisense Delivery
ανά: Agathe Eckenfelder, κ.ά.
Έκδοση: (2012-01-01)

Challenges to oligonucleotides-based therapeutics for Duchenne muscular dystrophy.
ανά: Goyenvalle, A, κ.ά.
Έκδοση: (2011)

AAV genome loss from dystrophic mouse muscles during AAV-U7 snRNA-mediated exon-skipping therapy
ανά: Le Hir, M, κ.ά.
Έκδοση: (2013)

Challenges to oligonucleotides-based therapeutics for Duchenne muscular dystrophy
ανά: Goyenvalle Aurélie, κ.ά.
Έκδοση: (2011-02-01)

Long-Term Efficacy of AAV9-U7snRNA-Mediated Exon 51 Skipping in mdx52 Mice
ανά: Philippine Aupy, κ.ά.
Έκδοση: (2020-06-01)

Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy
ανά: van Ommen Gert-Jan B, κ.ά.
Έκδοση: (2007-07-01)

From diagnosis to therapy in Duchenne muscular dystrophy
ανά: Babbs, A, κ.ά.
Έκδοση: (2020)

The potential of utrophin and dystrophin combination therapies for Duchenne muscular dystrophy
ανά: Guiraud, S, κ.ά.
Έκδοση: (2019)

New Approach for Antisense Oligonucleotide-Mediated Exon Skipping in Duchenne Muscular Dystrophy.
ανά: Aoki, Y, κ.ά.
Έκδοση: (2012)

Targeting Duchenne muscular dystrophy by skipping DMD exon 45 with base editors
ανά: Michael Gapinske, κ.ά.
Έκδοση: (2023-09-01)

Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis
ανά: Yuko Shimizu-Motohashi, κ.ά.
Έκδοση: (2018-06-01)

Rescue of cardiomyopathy through U7snRNA‐mediated exon skipping in Mybpc3‐targeted knock‐in mice
ανά: Christina Gedicke‐Hornung, κ.ά.
Έκδοση: (2013-05-01)

Possibility of exon skipping therapy for Duchenne muscular dystrophy in Russian patients: present and future
ανά: E. V. Zinina, κ.ά.
Έκδοση: (2024-09-01)

Progress in therapy for Duchenne muscular dystrophy.
ανά: Fairclough, R, κ.ά.
Έκδοση: (2011)

Progress in therapy for Duchenne muscular dystrophy
ανά: Fairclough, R, κ.ά.
Έκδοση: (2011)

Utrophin in the therapy of Duchenne Muscular Dystrophy
ανά: Potter, A, κ.ά.
Έκδοση: (2006)

Exon skipping peptide-pmos for correction of dystrophin in mouse models of duchenne muscular dystrophy
ανά: Betts, C, κ.ά.
Έκδοση: (2014)

Regenerative biomarkers for Duchenne muscular dystrophy
ανά: Guiraud, S, κ.ά.
Έκδοση: (2019)

Duchenne Muscular Dystrophy
ανά: J Gordon Millichap
Έκδοση: (1989-05-01)

Regenerative biomarkers for Duchenne muscular dystrophy
ανά: Simon Guiraud, κ.ά.
Έκδοση: (2019-01-01)

Therapeutic approaches for Duchenne muscular dystrophy
ανά: Roberts, TC, κ.ά.
Έκδοση: (2023)

Duchenne muscular dystrophy: recent insights in brain related comorbidities
ανά: Cyrille Vaillend, κ.ά.
Έκδοση: (2025-02-01)

Utrophin upregulation in Duchenne muscular dystrophy.
ανά: Hirst, R, κ.ά.
Έκδοση: (2005)

Challenges for antisense oligonucleotide-based therapeutics, in particular for exon 51-skipping in Duchenne muscular dystrophy
ανά: Aoki, Y, κ.ά.
Έκδοση: (2011)

CRISPR-Cas9-mediated exon skipping as a cardioprotective strategy in Duchenne muscular dystrophy
ανά: Harry Wilton-Clark, κ.ά.
Έκδοση: (2023-09-01)

Newborn screening of duchenne muscular dystrophy specifically targeting deletions amenable to exon-skipping therapy
ανά: Pablo Beckers, κ.ά.
Έκδοση: (2021-02-01)

Upper limb disease evolution in exon 53 skipping eligible patients with Duchenne muscular dystrophy
ανά: Charlotte Lilien, κ.ά.
Έκδοση: (2021-10-01)

Evaluation of 2’-Deoxy-2’-fluoro Antisense Oligonucleotides for Exon Skipping in Duchenne Muscular Dystrophy
ανά: Silvana M G Jirka, κ.ά.
Έκδοση: (2015-01-01)

Duchenne muscular dystrophy - past, present and future
ανά: Davies, K
Έκδοση: (2002)

Pharmacological advances for treatment in Duchenne muscular dystrophy
ανά: Guiraud, S, κ.ά.
Έκδοση: (2017)